SureTrader Advertisement
Home > Boards > US Listed > Biotechs >

Windtree Therapeutics, Inc. (WINT)

WINT RSS Feed
Add WINT Price Alert      Hide Sticky   Hide Intro
Moderator: wodehouse
Search This Board:
Last Post: 6/17/2016 11:53:52 AM - Followers: 110 - Board type: Free - Posts Today: 0

The Big Day is Coming!!!!!!!!!!


 The FDA classified the review of the Complete Response as a Class 2 review and established March 6, 2012 as the target action date under the Prescription Drug User Fee Act (PDUFA) to complete its review and potentially grant marketing approval for SURFAXIN.

 





Discovery Laboratories, Inc., a biotechnology company, engages in developing surfactant therapies to treat respiratory disorders and diseases based on its KL4 surfactant and capillary aerosol-generating technologies. Its development stage products include Surfaxin, a synthetic, peptide-containing surfactant in phase III clinical trial for the prevention of respiratory distress syndrome in premature infants; Surfaxin LS, a Phase III trial product to improve ease of use for healthcare practitioners; and Aerosurf, an aerosolized KL4 surfactant that has completed first pilot Phase II clinical trial for the treatment of respiratory distress syndrome in premature infants.

The company has a license agreement with Philip Morris USA Inc. to use its capillary aerosolization technology for use with pulmonary surfactants for the respiratory diseases and conditions; and a strategic alliance agreement with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products in Andorra, Greece, Italy, Portugal, and Spain.

Discovery Laboratories, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.



 

MUST READ!!!!!!!!!!!!!!!!!

  On May 11, 2011, the Company issued a press release highlighting the results of operations for the quarter ended March 31, 2011, and providing an update on its pipeline development as follows:
 
Surfaxin® (lucinactant) for the prevention of respiratory distress syndrome (RDS) in premature infants: The Company is conducting a comprehensive preclinical program to validate its optimized biological activity test (BAT), a key remaining issue that must be addressed to potentially gain U.S. Food and Drug Administration (FDA) marketing approval for Surfaxin in the United States.  The Company has had several interactions with the FDA intended to ensure that the comprehensive preclinical program would ultimately satisfy the FDA.  In January 2011, the Company announced that the FDA had provided guidance to increase the sample size of a specific data set by testing additional Surfaxin batches.  To comply with the FDA's suggestion, the Company has successfully manufactured eight Surfaxin batches and presently plans to manufacture two additional Surfaxin batches for use in the comprehensive preclinical program. The Company presently plans to complete all related analytical testing and concordance studies, and be in a position to file a Surfaxin Complete Response in the third quarter of 2011.
 
Surfaxin LSTM (lyophilized lucinactant) for neonatal RDS :  The Company continues to advance this program. Its plans for 2011 include establishing a commercial-scale manufacturing capability at a cGMP-compliant contract manufacturer with expertise in lyophilized formulations and seeking regulatory guidance from the FDA and the European Medicines Agency (EMA) for the planned clinical development program.
 
Aerosolization Technology :  Recently, at the 2011 Pediatric Academic Societies Annual Meeting (PAS), new data was presented including: (i) a collaborative study indicating that aerosolized KL4 surfactant significantly improved lung function and survival when treating Acute Lung Injury in a well established preclinical model of this severe respiratory condition, (ii) a dose-ranging assessment of aerosolized KL4 surfactant in a widely recognized preclinical model of RDS, demonstrating significant improvement in lung function, lung structural integrity and pulmonary inflammatory mediator profile following treatment with aerosolized KL4 surfactant versus controls, and (iii) a study highlighting the Company's novel patient interface technology intended to increase the efficiency of pulmonary aerosol drug delivery to patients requiring positive pressure ventilatory support.
 
 
2

 

 
 
Regarding the Company's lead aerosolized KL4 surfactant program, Aerosurf® (aerosolized lucinactant for neonatal RDS), data from the preclinical dose ranging assessment study presented at PAS mentioned above suggests that, out of several doses tested, KL4 surfactant delivered via the Company's proprietary capillary aerosol generator during a 20 to 30 minute dosing interval results in the most favorable physiologic outcomes.  This study provides guidance for future clinical dosing strategies for this program. The Company's plans for 2011 include finalizing the clinical and potential commercial design of the capillary aerosol generator, finalizing the clinical and potential commercial design for the novel patient interface, and seeking regulatory guidance in the U.S. and Europe for the planned development program.
 
For the quarter ending June 30, 2011, the Company projects cash outflow of $5.8 million.

 





 

Investor Relations Contacts

John G. Cooper
Executive Vice President, Chief Financial Officer
Discovery Laboratories, Inc.
2600 Kelly Road, Suite 100
Warrington, PA 18976
Tel. 215.488.9490
Fax. 215.488.9391
jcooper@discoverylabs.com


 



As of November 8, 2011, 24,499,497 shares of the registrant's common stock, par value $0.001 per share, were outstanding

As of  May 2, 2011, 24,178,502 shares of the registrant's common stock, par value $0.001 per share, were outstanding.  AutAeeeeee

Authorized 50 Mill

85 BM's 5-15-11



 

 

 

2010-11 Press Releases

 

May 13, 2011 10-Q http://ih.advfn.com/p.php?pid=nmona&article=47677338 

May 13, 2011 http://ih.advfn.com/p.php?pid=nmona&article=47666790       A Brighter Decade Ahead for Biotech - Equity Research on Discovery Laboratories and Mylan Inc   

May 11, 2011 8k http://ih.advfn.com/p.php?pid=nmona&article=47626029     

May 19, 2010
Discovery Labs Achieves Key Milestone Towards Potential Surfaxin® Approval

May 17, 2010
Discovery Labs' KL4 Surfactant Demonstrates Potential Protective Role for Lung Transplantation in Established Preclinical Model

May 14, 2010
Discovery Labs' Phase 2a Aerosurf® Study Published in Journal of Aerosol Medicine and Pulmonary Drug Delivery

May 5, 2010
Surfaxin LSTM Improves Pulmonary Function and Reduces Lung Inflammation in Established Model of Respiratory Distress Syndrome

April 28, 2010
Discovery Labs' KL4 Surfactant Data to be Presented at Pediatric Academic Societies Annual Meeting and American Thoracic Society International Conference

April 27, 2010
Discovery Labs Provides Updates on Surfaxin®, Other Key Programs and First Quarter 2010 Financial Results

March 10, 2010
Discovery Labs Reports Fourth Quarter 2009 Financial Results and Provides Business Update

February 23, 2010
Discovery Labs Announces Completion of $16.5 Million Public Offering

February 18, 2010
Discovery Labs Prices $16.5 Million Public Offering of Common Stock and Warrants

February 17, 2010
Discovery Labs Announces Proposed Public Offering of Common Stock and Warrants

February 16, 2010
Discovery Labs Receives FDA Guidance Regarding Pathway to Potential SURFAXIN® Approval

January 19, 2010
POPG, a Key Component of Discovery Labs KL4 Surfactant, Identified as a Novel Anti-Viral Therapeutic Approach

 



Management Team View Bio

W. Thomas Amick, Interim CEO

Russell Clayton, D.O.
Vice President, Academic and Medical Affairs, Acting Head, Regulatory Affairs and Preclinical Research

Kathryn Cole
Senior Vice President, Human Resources

John G. Cooper
Executive Vice President, Chief Financial Officer

David L. Lopez, C.P.A., Esq.
Executive Vice President, General Counsel

Charles F. Katzer
Senior Vice President, Manufacturing Operations

Thomas F. Miller, Ph.D., MBA
Senior Vice President, Commercialization & Corporate Development

Gerald J. Orehostky
Senior Vice President, Quality Operations

Robert Segal, M.D., F.A.C.P.
Senior Vice President, Medical & Scientific Affairs, Chief Medical Officer

Mary B. Templeton, Esq.
Senior Vice President, Deputy General Counsel

 



Do your own DD & trade smart

(DSCO) Pre-Market Trading     (DSCO) After Hours Trading

(DSCO) Short

Technical Indicators (Barchart) 

Yahoo! Finance (i.e Real-Time)

Last update: June 03,2010

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
WINT
Current Price
Volume:
Bid Ask Day's Range
SureTrader
WINT News: Windtree Awarded $1.0 million SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Ra... 07/14/2016 08:45:00 AM
WINT News: Current Report Filing (8-k) 07/13/2016 04:35:55 PM
WINT News: Confidential Treatment Order (ct Order) 07/01/2016 11:53:59 AM
WINT News: Current Report Filing (8-k) 06/23/2016 04:40:53 PM
WINT News: Current Report Filing (8-k) 06/22/2016 06:02:26 AM
PostSubject
#2946   Wow, two months since last post-then again not wodehouse 06/17/16 11:53:52 AM
#2945   Updated Website, nice logo (I think), definitely looks H2R 04/19/16 05:42:01 PM
#2944   Discovery Labs Changes Name to Windtree Therapeutics, Inc. N_B 04/18/16 02:18:35 PM
#2943   was the huge increase in share price due king oil 04/18/16 10:10:12 AM
#2942   Up 42% this week! H2R 04/15/16 04:43:31 PM
#2941   Impressed by comeback yesterday and nice gain today. wodehouse 04/14/16 02:37:06 PM
#2940   amazing comeback in share price on impressive volume. king oil 04/11/16 09:22:20 PM
#2939   Only 8.19M shares outstanding since the rs, according wodehouse 04/11/16 04:09:53 PM
#2938   I can't find any news but something is Phantom Lord 04/11/16 02:23:43 PM
#2937   Third up session in a row, good volume wodehouse 04/11/16 12:03:36 PM
#2936   I went back to the Quarterly CC and H2R 04/10/16 10:49:19 AM
#2935   Sorry, I really don't know. wodehouse 04/10/16 09:47:37 AM
#2934   Do you think Ph 3 is being planned, H2R 04/09/16 10:28:22 AM
#2933   Nice volume, closed at high of the day, wodehouse 04/08/16 04:11:24 PM
#2932   I didn't know of that article-every little bit helps! wodehouse 04/08/16 10:31:51 AM
#2931   And another 8% up?? The SmithOnStocks article? H2R 04/08/16 10:17:39 AM
#2930   Nice to see your post. Don't believe anything wodehouse 04/07/16 07:27:28 PM
#2929   Thanks wodehouse, H2R 04/07/16 06:56:00 PM
#2928   Look at Yahoo finance, Zacks' put out a wodehouse 04/07/16 04:41:10 PM
#2927   Up 17 % on April 7: I can't H2R 04/07/16 04:29:09 PM
#2926   "Earnings" report-will they have a product to produce wodehouse 03/24/16 09:35:46 AM
#2925   Damn autocorrect....ticker DaBukman 03/15/16 10:26:28 AM
#2924   DSCO ticket change...now POS. DaBukman 03/15/16 10:26:05 AM
#2923   Damn autocorrect DaBukman 03/11/16 11:17:01 AM
#2922   Simeon call the police! There's a murder DaBukman 03/11/16 11:16:44 AM
#2921   We get seemingly good news so we go wodehouse 02/02/16 11:30:55 AM
#2920   so we go down .02 Ah. No one wodehouse 02/01/16 07:39:44 PM
#2919   Good news, CEO changed out. wodehouse 02/01/16 06:53:39 PM
#2918   MONDAY SHOULD BE INTERESTING DAY HERE...dsco is going OB_WEALTH_INC 01/29/16 10:36:54 PM
#2917   It might finally be leveling off at this king oil 01/27/16 10:46:38 AM
#2916   So is management a bunch of total a**hole idiots?!!? N_B 01/26/16 10:09:21 AM
#2915   I wonder if they'll do another reverse split king oil 01/25/16 08:07:24 PM
#2914   wow, bid down to 96 cents king oil 01/25/16 06:32:17 PM
#2913   Ouch... What's the world record for least amount valeriana 01/25/16 02:25:54 PM
#2912   Looking like crap. wodehouse 01/25/16 12:28:52 PM
#2911   Looking good? N_B 01/25/16 11:33:01 AM
#2910   Looking good king oil 01/25/16 10:51:02 AM
#2909   Down to 2.10 now. Went as low N_B 01/22/16 11:20:54 AM
#2908   Before we know it, we will be back N_B 01/22/16 10:34:43 AM
#2907   Bad bad bad. Never fails. Always N_B 01/22/16 10:09:08 AM
#2906   Can't say we didn't expect it. wodehouse 01/21/16 05:15:46 PM
#2905   Discovery Labs Announces Reverse Stock Split N_B 01/21/16 05:00:54 PM
#2904   Does anyone know when about more clinical results valeriana 01/08/16 07:44:39 AM
#2902   Going sub-penny this year. DaBukman 01/06/16 11:45:33 AM
#2901   Watch for the 250k buy direct 01/01/16 10:02:50 PM
#2900   I guess they decided to announce that it wodehouse 12/30/15 07:55:52 AM
#2899   Well, a little news-this and a buck and wodehouse 12/29/15 04:18:54 PM
#2898   Not a rumor....it's a fact: nathanial 12/22/15 09:48:24 AM
#2897   Wonder why we are green today if rumor wodehouse 12/22/15 09:45:25 AM
#2896   Just got a proxy for a reverse split. nathanial 12/22/15 06:36:35 AM
PostSubject